Published in

American Association for the Advancement of Science, Science Advances, 30(8), 2022

DOI: 10.1126/sciadv.abo4577

Links

Tools

Export citation

Search in Google Scholar

SMAD4, activated by the TCR-triggered MEK/ERK signaling pathway, critically regulates CD8 <sup>+</sup> T cell cytotoxic function

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Transforming growth factor–β is well known to restrain cytotoxic T cell responses to maintain self-tolerance and to promote tumor immune evasion. In this study, we have investigated the role of SMAD4, a core component in the TGF-β signaling pathway, in CD8 + T cells. Unexpectedly, we found that SMAD4 was critical in promoting CD8 + T cell function in both tumor and infection models. SMAD4-mediated transcriptional regulation of CD8 + T cell activation and cytotoxicity was dependent on the T cell receptor (TCR) but not TGF-β signaling pathway. Following TCR activation, SMAD4 translocated into the nucleus, up-regulated genes encoding TCR signaling components and cytotoxic molecules in CD8 + T cells and thus reinforced T cell function. Biochemically, SMAD4 was directly phosphorylated by ERK at Ser 367 residue following TCR activation. Our study thus demonstrates a critical yet unexpected role of SMAD4 in promoting CD8 + T cell–mediated cytotoxic immunity.